Method for attenuating eosinophils-driven inflammation using a composition for mucosal administration
AssigneeAdvagene Biopharma Co., Ltd.
InventorsHan-Pin KUO, Yu-Shen HSU, Ming-I CHANG, Yi-Shiuh HWANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method for treating a subject having eosinophil-associated inflammation, such as severe asthma, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin (LT).
Claims20
A method for treating a subject with eosinophil-associated inflammation in respiratory tissues and anatomically or immunologically adjacent tissues, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli heat-labile toxin (LT), wherein the composition is administered via a mucosal route.
Dependencies are inferred from the claim text.